Cassava Sciences Inc (SAVA)

$2.44 +0.15 (6.55%)
Market Cap 110.63M
Revenue (ttm) 0.00
Net Income (ttm) -24.34M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 1,259,800
Avg Vol 972,302
Day's Range N/A - N/A
Shares Out 48.31M
Stochastic %K 63%
Beta -2.05
Analysts Strong Buy
Price Target $2.00

Company Profile

Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. Cassava Sciences, Inc. was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. The company w...

Industry: Biotechnology
Sector: Healthcare
Phone: 512-501-2444
Address:
6801 N. Capital of Texas Highway, Suite 300 Building 1, Austin, United States
bigron8671
bigron8671 Aug. 5 at 6:34 PM
$SAVA that's a lot of neutral trades!
0 · Reply
SniperPro
SniperPro Aug. 5 at 4:40 PM
$SAVA $LXRX $PLUG $RKT $KOSS 🤩🧨🚀🔥📈💎🙌💎 🔥💯 They can try to hold us down — but we won't just push back, we'll break through... FORWARD!!!🤑🤑🤑 ...
0 · Reply
AVXL4theWin
AVXL4theWin Aug. 5 at 4:34 PM
$SAVA curing mice once again! And the cycle continues….
1 · Reply
MarcoFla99
MarcoFla99 Aug. 5 at 4:22 PM
$SAVA Human trial is 2026? What a waste of time,imo
0 · Reply
MarcoFla99
MarcoFla99 Aug. 5 at 4:21 PM
$SAVA Todays PR was a follow up from the 6-30 PR?
0 · Reply
dadatr8der
dadatr8der Aug. 5 at 3:36 PM
$SAVA 💯
0 · Reply
Pineapple1
Pineapple1 Aug. 5 at 3:20 PM
$SAVA Its almost as if they have something worthwhile to add to some kind of disease treatment. The games people play.
0 · Reply
bigron8671
bigron8671 Aug. 5 at 3:05 PM
$SAVA Maybe a few more neutral trades, lol
0 · Reply
BambooC
BambooC Aug. 5 at 2:48 PM
$SAVA 3+ eow?
0 · Reply
Pimpeanut
Pimpeanut Aug. 5 at 2:43 PM
$SAVA pump and dumb scheme… first they had a cure for Alzheimer’s now it’s a cure for epilepsy 💩💩💩🚽🚽🚽🚽
0 · Reply
Latest News on SAVA
Cassava Sciences Reports Positive Preclinical Study Evaluating Simufilam for TSC-Related Epilepsy

Aug 4, 2025, 7:30 AM EDT - 1 day ago

Cassava Sciences Reports Positive Preclinical Study Evaluating Simufilam for TSC-Related Epilepsy

Cassava Presents Promising Preclinical Simufilam Data at TSC Alliance Meeting

Jun 30, 2025, 7:00 AM EDT - 5 weeks ago

Cassava Presents Promising Preclinical Simufilam Data at TSC Alliance Meeting

Cassava Appoints Angélique Bordey, PhD, to Enhance Preclinical Program in TSC

May 1, 2025, 7:30 AM EDT - 3 months ago

Cassava Appoints Angélique Bordey, PhD, to Enhance Preclinical Program in TSC

Cassava Announces Retirement of Chief Medical Officer, Dr. Jim Kupiec, and Appointment of Dr. Jack Moore as Senior Vice President, Clinical Development

Apr 21, 2025, 4:30 PM EDT - 3 months ago

Cassava Announces Retirement of Chief Medical Officer, Dr. Jim Kupiec, and Appointment of Dr. Jack Moore as Senior Vice President, Clinical Development

Cassava Sciences must face malicious prosecution lawsuit over Alzheimer's drug

Mar 26, 2025, 3:49 PM EDT - 4 months ago

Cassava Sciences must face malicious prosecution lawsuit over Alzheimer's drug

Cassava Sciences Discontinues Developing Simufilam For Alzheimer's After Another Phase 3 Trial Flop

Mar 25, 2025, 10:42 AM EDT - 4 months ago

Cassava Sciences Discontinues Developing Simufilam For Alzheimer's After Another Phase 3 Trial Flop

Cassava Sciences Reports Topline Phase 3 REFOCUS-ALZ Data

Mar 25, 2025, 8:05 AM EDT - 4 months ago

Cassava Sciences Reports Topline Phase 3 REFOCUS-ALZ Data

Cassava Sciences Reports 2024 Financial Results and Provides Business Update

Mar 3, 2025, 7:30 AM EST - 5 months ago

Cassava Sciences Reports 2024 Financial Results and Provides Business Update

Lead Plaintiff Deadline on February 10, 2025 for SAVA Investors - Kessler Topaz Meltzer & Check, LLP Encourages Investors with Losses to Contact the Firm

Feb 9, 2025, 10:45 AM EST - 6 months ago

Lead Plaintiff Deadline on February 10, 2025 for SAVA Investors - Kessler Topaz Meltzer & Check, LLP Encourages Investors with Losses to Contact the Firm

SAVA Deadline: Rosen Law Firm Urges Cassava Sciences, Inc. (NASDAQ: SAVA) Stockholders with Large Losses to Contact the Firm for Information About Their Rights

Feb 7, 2025, 12:08 PM EST - 6 months ago

SAVA Deadline: Rosen Law Firm Urges Cassava Sciences, Inc. (NASDAQ: SAVA) Stockholders with Large Losses to Contact the Firm for Information About Their Rights

Shareholders of Cassava Sciences, Inc. Should Contact The Gross Law Firm Before February 10, 2025 to Discuss Your Rights - SAVA

Feb 3, 2025, 5:45 AM EST - 6 months ago

Shareholders of Cassava Sciences, Inc. Should Contact The Gross Law Firm Before February 10, 2025 to Discuss Your Rights - SAVA

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cassava

Jan 23, 2025, 2:47 PM EST - 6 months ago

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cassava

Cassava Sciences Provides a Business Update

Jan 7, 2025, 4:30 PM EST - 7 months ago

Cassava Sciences Provides a Business Update

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of February 10, 2025 in Cassava Sciences, Inc. Lawsuit - SAVA

Dec 23, 2024, 5:45 AM EST - 8 months ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of February 10, 2025 in Cassava Sciences, Inc. Lawsuit - SAVA

DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cassava

Dec 18, 2024, 10:53 AM EST - 8 months ago

DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cassava

Rosen Law Firm Urges Cassava Sciences, Inc. (NASDAQ: SAVA) Stockholders with Large Losses in Excess of $100K to Contact the Firm for Information About Their Rights

Dec 13, 2024, 1:16 PM EST - 8 months ago

Rosen Law Firm Urges Cassava Sciences, Inc. (NASDAQ: SAVA) Stockholders with Large Losses in Excess of $100K to Contact the Firm for Information About Their Rights

Bronstein, Gewirtz & Grossman, LLC Encourages Cassava Sciences, Inc. (SAVA) Shareholders to Inquire about Securities Investigation

Dec 10, 2024, 10:00 AM EST - 8 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Cassava Sciences, Inc. (SAVA) Shareholders to Inquire about Securities Investigation

Bronstein, Gewirtz & Grossman, LLC Is Investigating Cassava Sciences, Inc. (SAVA) And Encourages Shareholders to Connect

Dec 9, 2024, 10:00 AM EST - 8 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Cassava Sciences, Inc. (SAVA) And Encourages Shareholders to Connect

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Cassava Sciences, Inc. (SAVA) And Encourages Shareholders to Reach Out

Dec 8, 2024, 10:00 AM EST - 8 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Cassava Sciences, Inc. (SAVA) And Encourages Shareholders to Reach Out

bigron8671
bigron8671 Aug. 5 at 6:34 PM
$SAVA that's a lot of neutral trades!
0 · Reply
SniperPro
SniperPro Aug. 5 at 4:40 PM
$SAVA $LXRX $PLUG $RKT $KOSS 🤩🧨🚀🔥📈💎🙌💎 🔥💯 They can try to hold us down — but we won't just push back, we'll break through... FORWARD!!!🤑🤑🤑 ...
0 · Reply
AVXL4theWin
AVXL4theWin Aug. 5 at 4:34 PM
$SAVA curing mice once again! And the cycle continues….
1 · Reply
MarcoFla99
MarcoFla99 Aug. 5 at 4:22 PM
$SAVA Human trial is 2026? What a waste of time,imo
0 · Reply
MarcoFla99
MarcoFla99 Aug. 5 at 4:21 PM
$SAVA Todays PR was a follow up from the 6-30 PR?
0 · Reply
dadatr8der
dadatr8der Aug. 5 at 3:36 PM
$SAVA 💯
0 · Reply
Pineapple1
Pineapple1 Aug. 5 at 3:20 PM
$SAVA Its almost as if they have something worthwhile to add to some kind of disease treatment. The games people play.
0 · Reply
bigron8671
bigron8671 Aug. 5 at 3:05 PM
$SAVA Maybe a few more neutral trades, lol
0 · Reply
BambooC
BambooC Aug. 5 at 2:48 PM
$SAVA 3+ eow?
0 · Reply
Pimpeanut
Pimpeanut Aug. 5 at 2:43 PM
$SAVA pump and dumb scheme… first they had a cure for Alzheimer’s now it’s a cure for epilepsy 💩💩💩🚽🚽🚽🚽
0 · Reply
BambooC
BambooC Aug. 5 at 2:35 PM
$SAVA 👀👀
0 · Reply
WallStreetBuyDip
WallStreetBuyDip Aug. 5 at 1:46 PM
My only strategy since 2019 has been to buy when H% is low. Nothing else. Keep it simple and consistent. The results prove again and again why I‘ll only stick with this strategy Will trade $SAVA like how I did for others
0 · Reply
OnlyFibs
OnlyFibs Aug. 4 at 11:37 PM
$SAVA ER out time to explode to upside, follow me! #hovdid
0 · Reply
ZacksResearch
ZacksResearch Aug. 4 at 5:47 PM
$SAVA aiming for a new frontier in epilepsy treatment? 🧠⚡ Simufilam showed a dose-dependent reduction in seizures in a validated TSC mouse model — building on prior Yale research and pointing to a potential first-in-class option for treatment-resistant epilepsy. See what Wall Street expects next 👉 https://www.zacks.com/stock/research/SAVA/price-target-stock-forecast?cid=sm-stocktwits-0-price_target-oc-5837&ADID=SYND_STOCKTWITS_TWEET_0_PRICETARGET_OC_5837
0 · Reply
dadatr8der
dadatr8der Aug. 4 at 5:30 PM
$SAVA 💯
0 · Reply
CharlieeMungerTWITS
CharlieeMungerTWITS Aug. 4 at 3:11 PM
$CGTX $SAVA
0 · Reply
BambooC
BambooC Aug. 4 at 2:32 PM
$SAVA won’t be surprised to see 4
1 · Reply
BambooC
BambooC Aug. 4 at 2:31 PM
$SAVA
0 · Reply
Pineapple1
Pineapple1 Aug. 4 at 2:17 PM
$SAVA Vapor, exit stage right.
1 · Reply
zecca1889
zecca1889 Aug. 4 at 1:56 PM
$SAVA Couldn't it have been 22 instead of 2.22? Where does Barbier live, I want to talk to him?
0 · Reply
Arttard
Arttard Aug. 4 at 1:04 PM
$SAVA it will go up without volume?
0 · Reply
rlichgolf
rlichgolf Aug. 4 at 12:59 PM
$SAVA todays data is good for mice but a long way from humans. Gita
0 · Reply